BACKGROUND: Temporal changes in HIV-1 resistance both reflect and influence the clinical use of antiretrovirals (ARVs). OBJECTIVE: To determine temporal trends in reduced susceptibility to ARVs and resistance mutations in routine clinical samples (RCS) from HIV infected patients. STUDY DESIGN: Calculated fold-changes (FC) for ARVs were determined for viral genotypes from RCS received between July 1998 and June 2007 using vircoTYPE HIV-1 (Version 4.2.01). The prevalence of isolates with clinically relevant reduced susceptibility and of resistance mutations were determined for consecutive 6-month periods. RESULTS: 242,003 RCS were identified. The prevalence of RCS exhibiting reduced susceptibility to > or =1 drug among any of three ARV classes decreased from 82% to 66.5% and of these, to > or =1 drug in each of the three ARV classes and from 30.5% to 15.7% from December 98 to June 07 (p< or =0.0001). The prevalence of mutations associated with NRTI, NNRTI and PI resistance generally reflected evolving use of these drug classes. Among fully susceptible RCS, isolates that exhibited resistance mutations were rare. CONCLUSIONS: Clinically relevant reduced susceptibility to ARVs declined over the 9-year period. There was a general higher prevalence of reduced susceptibility to RT inhibitors than to PIs.
BACKGROUND: Temporal changes in HIV-1 resistance both reflect and influence the clinical use of antiretrovirals (ARVs). OBJECTIVE: To determine temporal trends in reduced susceptibility to ARVs and resistance mutations in routine clinical samples (RCS) from HIV infectedpatients. STUDY DESIGN: Calculated fold-changes (FC) for ARVs were determined for viral genotypes from RCS received between July 1998 and June 2007 using vircoTYPE HIV-1 (Version 4.2.01). The prevalence of isolates with clinically relevant reduced susceptibility and of resistance mutations were determined for consecutive 6-month periods. RESULTS: 242,003 RCS were identified. The prevalence of RCS exhibiting reduced susceptibility to > or =1 drug among any of three ARV classes decreased from 82% to 66.5% and of these, to > or =1 drug in each of the three ARV classes and from 30.5% to 15.7% from December 98 to June 07 (p< or =0.0001). The prevalence of mutations associated with NRTI, NNRTI and PI resistance generally reflected evolving use of these drug classes. Among fully susceptible RCS, isolates that exhibited resistance mutations were rare. CONCLUSIONS: Clinically relevant reduced susceptibility to ARVs declined over the 9-year period. There was a general higher prevalence of reduced susceptibility to RT inhibitors than to PIs.
Authors: Prema Menezes; David Rosen; David A Wohl; Nichole Kiziah; Joseph Sebastian; Joseph J Eron; Becky White Journal: AIDS Res Hum Retroviruses Date: 2012-11-19 Impact factor: 2.205
Authors: Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu Journal: Antimicrob Agents Chemother Date: 2011-05-31 Impact factor: 5.191
Authors: Patrick Keating; Anastasia Pharris; Katrin Leitmeyer; Stefania De Angelis; Annemarie Wensing; Andrew J Amato-Gauci; Eeva Broberg Journal: Euro Surveill Date: 2017-12
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632